PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24723F0229Pharmaceuticals — Amicus Therapeutics Us, LLC

Amicus Therapeutics Us, LLC holds $3.4M across 74 federal awards, concentrated at Department of Veterans Affairs (VA). This PIID sits alongside 2 related awards under parent 36F79719D0108. The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended Sep 30, 2023 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

247-Network Contract Office 7 (36C247)

Awarding office

Amicus Therapeutics Us, LLC

Recipient

Sep 30, 2023

PoP end

$181K

Obligated

$181K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Amicus Therapeutics Us, LLC — $90

Contract facts

Federal

Contract number36C24723F0229

Also listed as36C247-23-F-0229

Also listed as36F79719D0108-36C24723F0229

Agency247-Network Contract Office 7 (36C247)

Awarding office247-Network Contract Office 7 (36C247)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentAmicus Therapeutics Us, LLC

CAGE867U3

UEIKLJFGENKMD89

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79719D0108

Place of performancePHILADELPHIA PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startFeb 6, 2023

PoP end (current)Sep 30, 2023

Obligated$181K

Current value$181K

Potential value$181K

PHARMACEUTICALS is a federal award for 247-Network Contract Office 7 (36C247) held by Amicus Therapeutics Us, LLC. Estimated value $181K ($181K obligated). Current period of performance ends Sep 30, 2023. Last award drew 1 bidder. Place of performance: PHILADELPHIA PA.

Recompete timing

Public

● Past PoP end (1056 days ago)

Current PoP ended Sep 30, 2023 (1056 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Amicus Therapeutics Us, LLC — $3.4M obligated across 74 awards (firm-wide, all agencies).

Sole agency: Department of Veterans Affairs (VA)

Department of Veterans Affairs (VA)$3.4M · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C25926F0001

GALAFOLD 123 MG CAPSULE - NTE

$295K

Nov 14, 2026

36C24726F0100

GALAFOLD MEDICATION

$228K

Feb 22, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C24723F0229?

36C24723F0229 (Pharmaceuticals) is a 247-Network Contract Office 7 (36C247) award with a potential value of $181K, currently held by Amicus Therapeutics Us, LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C247-23-F-0229?

36C247-23-F-0229 is the dashed form of PIID 36C24723F0229 (Pharmaceuticals), held by Amicus Therapeutics Us, LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C24723F0229?

247-Network Contract Office 7 (36C247) awarded 36C24723F0229 to Amicus Therapeutics Us, LLC (potential $181K).

Who is the incumbent on 36C24723F0229?

Amicus Therapeutics Us, LLC is the incumbent with $3.4M across 74 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2023.

When does Amicus Therapeutics Us, LLC’s 36C24723F0229 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 25, 2026 · refreshed monthlyLatest procurement action Feb 7, 2023